Hesperidin supplementation and endothelial function in patients with metabolic syndrome: a randomised, controlled crossover trial
Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P, Senese N, Tesauro M, Lauro D, Cardillo C, Quon MJ
Published in Journal of Clinical Endocrinology and Metabolism
Methodology
Three-week randomised placebo-controlled crossover trial of hesperidin 500 mg daily in patients with metabolic syndrome, with flow-mediated dilation as primary outcome
Key Findings
Hesperidin increased flow-mediated dilation by 24% and reduced circulating inflammatory markers versus placebo, without changing insulin sensitivity.
Conclusions
Hesperidin improves endothelial function in metabolic syndrome without altering glucose handling.
Limitations
Small crossover sample; short exposure; surrogate outcome.
Supplements Studied
Hesperidin increased flow-mediated dilation by 24% and reduced circulating inflammatory markers versus placebo.
Outcomes Measured
Hesperidin increased flow-mediated dilation by 24% versus placebo.
Hesperidin increased flow-mediated dilation by 24% and reduced circulating inflammatory markers versus placebo, without changing insulin sensitivity.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.